Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
The novel SARS-Coronavirus-2 becomes activated and is infective after interacting with the human TMPRSS2 enzyme, as it primes the virus to enter and hijack lung cells for viral replication. By designing drugs using a strategy that has shown success in inhibiting enzymes structurally similar to TMPRSS2 and understanding the exact shape of this enzyme in greater detail, highly specific drugs can be engineered to block SARS-CoV-2 activation and alleviate symptoms contributing to COVID-19 mortality. Through a collaboration between BC Cancer and the Structural Genomics Consortium, promising COVID-19 therapeutics predicted to block TMPRSS2 can be produced and tested experimentally, then translated to clinical study in an accelerated manner through the combined expertise of leading scientists and clinicians.
Francois Benard
Bryan Fraser
Structural Genomics Consortium
Other
Professional, scientific and technical services
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.